Buscar
Anika Therapeutics Inc
ANIKAñadir a la lista de seguimiento
19.250USD
+1.180+6.53%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
257.12MCap. mercado
PérdidaP/E TTM
Más Datos de Anika Therapeutics Inc Compañía
Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.
Información de Anika Therapeutics Inc
Símbolo de cotizaciónANIK
Nombre de la empresaAnika Therapeutics Inc
Fecha de salida a bolsaMay 16, 1985
Director ejecutivoBlanchard (Cheryl Renee)
Número de empleados288
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 16
Dirección32 Wiggins Ave
CiudadBEDFORD
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal01730-2315
Teléfono17814579000
Sitio Webhttps://anika.com/
Símbolo de cotizaciónANIK
Fecha de salida a bolsaMay 16, 1985
Director ejecutivoBlanchard (Cheryl Renee)
Ejecutivos de Anika Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Stephen D. (Steve) Griffin
Mr. Stephen D. (Steve) Griffin
Chief Financial Officer, Chief Operating Officer, Executive Vice President
Chief Financial Officer, Chief Operating Officer, Executive Vice President
90.25K
+10.05%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
52.97K
+19.64%
Dr. Glenn R. Larsen, Ph.D.
Dr. Glenn R. Larsen, Ph.D.
Independent Director
Independent Director
50.26K
--
Mr. Joseph H. (Joe) Capper
Mr. Joseph H. (Joe) Capper
Independent Director
Independent Director
30.80K
+33.77%
Mr. William R. (Bill) Jellison
Mr. William R. (Bill) Jellison
Independent Director
Independent Director
23.10K
--
Dr. Cheryl Renee Blanchard, Ph.D.
Dr. Cheryl Renee Blanchard, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Susan L. N. Vogt
Ms. Susan L. N. Vogt
Independent Director
Independent Director
--
--
Mr. David B. Colleran, J.D.
Mr. David B. Colleran, J.D.
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
--
--
Mr. John Bell (Jack) Henneman, III
Mr. John Bell (Jack) Henneman, III
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Stephen O. Richard
Mr. Stephen O. Richard
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Stephen D. (Steve) Griffin
Mr. Stephen D. (Steve) Griffin
Chief Financial Officer, Chief Operating Officer, Executive Vice President
Chief Financial Officer, Chief Operating Officer, Executive Vice President
90.25K
+10.05%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
52.97K
+19.64%
Dr. Glenn R. Larsen, Ph.D.
Dr. Glenn R. Larsen, Ph.D.
Independent Director
Independent Director
50.26K
--
Mr. Joseph H. (Joe) Capper
Mr. Joseph H. (Joe) Capper
Independent Director
Independent Director
30.80K
+33.77%
Mr. William R. (Bill) Jellison
Mr. William R. (Bill) Jellison
Independent Director
Independent Director
23.10K
--
Dr. Cheryl Renee Blanchard, Ph.D.
Dr. Cheryl Renee Blanchard, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Anika Therapeutics Inc?
Los cinco principales accionistas de Anika Therapeutics Inc son: Mr. Stephen D. (Steve) Griffin
¿Cuántas instituciones poseen acciones de Anika Therapeutics Inc (ANIK)?
A fecha de 2026Q1, 264 instituciones poseen acciones de Anika Therapeutics Inc, con un valor de mercado combinado de aproximadamente 12.85M, lo que representa el 96.55% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -1611291.00.
¿Cuál es la mayor fuente de ganancias de Anika Therapeutics Inc?
El 2026Q1, el segmento empresarial OEM Channel generó la ganancia más alta para Anika Therapeutics Inc, ascendiendo a 64.41M y representando el 57.09% de la ganancia total.